Arqt stock forecast.

Arcutis Biotherapeutics Inc () Stock Market info Recommendations: Buy or sell Arcutis Biotherapeutics stock? Wall Street Stock Market & Finance report, prediction for the …The consensus price target of analysts on Wall Street is $24.50, which implies an increase of 91.02% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $50.00 respectively. As a result, ARQT is trading at a discount of -2172.73% off the target high and -81.82% off the low.What this means: InvestorsObserver gives Arcutis Biotherapeutics Inc (ARQT) an overall rank of 33, which is below average. Arcutis Biotherapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 33 means that 67% of stocks appear more favorable to our system. Jun 9, 2023 · TD Cowen has a $65 price target on ARQT shares, while Mizuho’s price target stands at $57. Morgan Stanley also has a $47 price target and ‘Overweight’ rating on the stock.

Find the latest BioVie Inc. (BIVI) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W. Mid Term ...

Ocuphire Pharma. 's revenue in 2023 is $57,208,000.. On average, 1 Wall Street analysts forecast OCUP's revenue for 2023 to be $471,541,208, with the lowest OCUP revenue forecast at $471,541,208, and the highest OCUP revenue forecast at $471,541,208. Shares of ARQT fell 6.9% in extended trading. ARQT added that it intends to grant the underwriters a 30-day option to purchase up to an additional $15M of its common shares. Press Release

Stock Price Forecast. The 26 analysts offering 12-month price forecasts for Halliburton Co have a median target of 49.50, with a high estimate of 56.00 and a low estimate of 44.00.Frank Watanabe. https://www.arcutis.com. Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic ...Arcutis Biotherapeutics' CEO is Frank Watanabe, appointed in Jan 2016, has a tenure of 7.83 years. total yearly compensation is $4.58M, comprised of 12.9% salary and 87.1% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth $798.75K. The average tenure of the management team and the board of ...Oct 20, 2023 · The shares of common stock are being sold at a public offering price of $2.50 per share and the pre-funded warrants are being sold at a public offering price of $2.4999 per pre-funded warrant ...

Frank Watanabe. https://www.arcutis.com. Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic ...

The average Ocuphire Pharma stock price prediction forecasts a potential upside of 585.19% from the current OCUP share price of $2.70. What is OCUP's forecast return on equity (ROE) for 2023-2026? (NASDAQ: OCUP) forecast ROE is …

DraftKings shares gained 16.5% to close at $33.75 on Friday. See how other analysts view this stock. Keybanc cut the price target for Restaurant Brands International Inc. (NYSE:QSR) from $85 to ...On Friday, Arcutis Biotherapeutics Inc [NASDAQ:ARQT] saw its stock fall -4.75% to $1.90. On the same session, the stock had its day’s lowest price of $1.80, but rose to a high of $2.06. Over the last five days, the stock has lost -21.93%. Arcutis Biotherapeutics Inc shares have fallen nearly -87.13% since the year began.However, Arcutis BiotherapeuticsI's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from ...Oct 20, 2023 · The shares of common stock are being sold at a public offering price of $2.50 per share and the pre-funded warrants are being sold at a public offering price of $2.4999 per pre-funded warrant ... Arcutis Biotherapeutics price target lowered to $8 from $22 at Needham November 6, 2023TipRanks. Get Arcutis Biotherapeutics Inc (ARQT:NASDAQ) real-time stock quotes, news, price and financial ...How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding.Nov 29, 2023 · The Arcutis Biotherapeutics Inc stock price fell by -0.529% on the last day (Wednesday, 22nd Nov 2023) from $1.89 to $1.88. During the last trading day the stock fluctuated 17.51% from a day low at $1.77 to a day high of $2.08. The price has fallen in 6 of the last 10 days and is down by -14.55% for this period.

Is Arcutis Biotherapeutics Stock Undervalued? The current Arcutis Biotherapeutics share price is $1.95. The Score for ARQT is 8, which is 84% below its historic median score of 50, and infers higher risk than normal. ARQT is currently trading in the 0-10% percentile range relative to its historical Stock Score levels.Weather forecasts are essential tools for planning our daily activities, especially when it comes to the next 10 days. Understanding a weather 10 day forecast can help us make informed decisions about outdoor events, travel plans, or even w...Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for ARQT stock stock is $27.25, which predicts an increase of …Mumbai Stock Forecast . Bombay Stock Exchange Stock Forecast BSE Share Price Predictions with Smart Prognosis Chart - 2023-2024 You can find here the Best Indian Stocks to buy! Showing 1-100 of 3,290 items. Forecast Range Filter. From % To % Filter Reset / Default. Rating Name Price (INR) ...Forecasting is the use of historic data to determine the direction of future trends. Businesses utilize forecasting to determine how to allocate their budgets or plan for anticipated expenses for ...The average Bit Digital stock price prediction forecasts a potential upside of 55.04% from the current BTBT share price of $2.58. What is BTBT's forecast return on equity (ROE) for 2023-2024? (NASDAQ: BTBT) forecast ROE is N/A, which is considered weak.

Within the last quarter, Arcutis Biotherapeutics (NASDAQ:ARQT) has observed the following analyst ratings: In the last 3 months, 7 analysts have offered 12-month price targets for Arcutis ...

Arcutis Biotherapeutics Inc Price (ARQT) Daily Price Prediction Charts. ... HKEX (Hong Kong) Stock Forecasts; All Stocks (from 50+ Exchanges) Stocks Under . Stocks Under 10 Cents; Stocks Under 50 Cents; Stocks Under 1 USD; Stocks Under 5 USD; Stocks Under 10 USD; Stocks Under 20 USD;Dec 1, 2023 · 9 analysts have issued twelve-month target prices for Arcutis Biotherapeutics' shares. Their ARQT share price targets range from $6.00 to $57.00. On average, they anticipate the company's stock price to reach $29.67 in the next year. This suggests a possible upside of 1,390.8% from the stock's current price. Eurozone December Investor Confidence -16.8, Short of -15.0 Forecast about 1 hour ago The Week Ahead: The RBA, China and the US Jobs Report 1 day ago Five Things to Know in Crypto This Week: BTC ...Arcutis Biotherapeutics Stock Chart and Share Price Forecast, Short-Term "ARQT" Stock Prediction for Next Days and Weeks Walletinvestor.com Arcutis Biotherapeutics Inc (ARQT) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 As of May 30, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $7.81. Arcutis Biotherapeutics Inc is down 7.02% from its previous closing price of $8.40. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $8.11 and $8.57. Currently, there are 61.17 million shares of Arcutis Biotherapeutics Inc ...ARQT Stock Performance Soars on November 3, 2023 with Positive Analyst Sentiment and Potential 1,269.29% Increase ARQT stock had a significant performance on November 3, 2023. According to data from CNN Money, eight analysts have offered 12-month price forecasts for Arcutis Biotherapeutics Inc, with a median target of $33.00.Arcutis Biotherapeutics Stock Price, News & Analysis (NASDAQ:ARQT) $1.99 +0.15 (+8.15%) (As of 12/1/2023 ET) Compare Today's Range $1.76 $2.00 50-Day Range $1.84 $5.83 52-Week Range $1.76 $18.04 Volume 2.93 million shs Average Volume 2.67 million shs Market Capitalization $187.82 million P/E Ratio N/A Dividend YieldPrice target. 15.86R USD +13.83 +681.14%. The 7 analysts offering 1 year price forecasts for Arcutis Biotherapeutics, Inc. have a max estimate of 44.00 and a min estimate of 4.00.Arcutis Biotherapeutics Inc’s Stock Price as of Market Close. As of March 06, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $14.54. Arcutis Biotherapeutics Inc is down 6.5% from its previous closing price of $15.55. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $15.55 and $16.45.

Arcutis Biotherapeutics Inc (ARQT) stock is down -19.17% while the S&P 500 has gained 0.24% as of 11:18 AM on Wednesday, May 10. ARQT has fallen -$2.84 from the previous closing price of $14.82 on volume of 1,864,299 shares. Over the past year the S&P 500 has gained 3.46% while ARQT has fallen -36.41%.

Celebrations may be in order for Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company.The ...

Oct 13, 2023 · Oct. 13, 2023, 11:00 AM Arcutis Biotherapeutics (NASDAQ:ARQT) has observed the following analyst ratings within the last quarter: These 6 analysts have an average price target of $34.83 versus... Nov 10, 2023 · Future criteria checks 2/6. Arcutis Biotherapeutics is forecast to grow earnings and revenue by 42.6% and 50.2% per annum respectively. EPS is expected to grow by 52.7% per annum. Return on equity is forecast to be -1340.1% in 3 years. According to . 1 Wall Street analyst that have issued a 1 year THRD price target, the average THRD price target is $7.00, with the highest THRD stock price forecast at $7.00 and the lowest THRD stock price forecast at $7.00.Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. After Hours trades will be posted from 4:15 p ...ARQT Arcutis Biotherapeutics Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ)TD Cowen has a $65 price target on ARQT shares, while Mizuho’s price target stands at $57. Morgan Stanley also has a $47 price target and ‘Overweight’ rating on the stock.Nov 6, 2023 · Analyst projections state that ARQT is forecast to be at a low of $4.00 and a high of $50.00. In order for the stock price to hit the forecast high, the stock would need to plunge -1949.18% from its current level, while the stock would need to crash -63.93% from its current level to reach the projected low. The average one-year price target for ARQT / Arcutis Biotherapeutics Inc is $11.39. The forecasts range from a low of $4.04 to a high of $21. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to ...Represents the company's profit divided by the outstanding shares of its common stock. Fiscal Q4 2023 ended 9/30/23. Fiscal Q4 2023 ended 9/30/23. Get the latest Arqit Quantum Inc (ARQQ) real-time ...The average one-year price target for ARQT / Arcutis Biotherapeutics Inc is $11.39. The forecasts range from a low of $4.04 to a high of $21. A stock’s price target is the price at …Dec 3, 2023 · Frank Watanabe. https://www.arcutis.com. Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic ... The Arcutis Biotherapeutics Inc stock price fell by -0.529% on the last day (Wednesday, 22nd Nov 2023) from $1.89 to $1.88. During the last trading day the stock fluctuated 17.51% from a day low at $1.77 to a day high of $2.08. The price has fallen in 6 of the last 10 days and is down by -14.55% for this period.

Nov 6, 2023 · Analyst projections state that ARQT is forecast to be at a low of $4.00 and a high of $50.00. In order for the stock price to hit the forecast high, the stock would need to plunge -1949.18% from its current level, while the stock would need to crash -63.93% from its current level to reach the projected low. Arcutis has launched Zoryve, a topical cream for the treatment of psoriasis, and is focused on transitioning to a commercial-stage company. Read more about ARQT stock here.The consensus price target of analysts on Wall Street is $36.63, which implies an increase of 91.73% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6.00 and $57.00 respectively. As a result, ARQT is trading at a discount of -1781.19% off the target high and -98.02% off the low.Technical analysis forecast for Arcutis Biotherapeutics Stock is that its in a downtrend for shortterm, and I will avoid taking a BUY or a LONG trade in this ...Instagram:https://instagram. day trade coursetgtx stock forecasthomes for healthcare professionalscarson group omaha According to the issued ratings of 9 analysts in the last year, the consensus rating for Arcutis Biotherapeutics stock is Moderate Buy based on the current 3 hold ratings and 6 buy ratings for ARQT. The average twelve-month price prediction for Arcutis Biotherapeutics is $29.67 with a high price target of $57.00 and a low price target of $6.00 ... laundry side hustletesla's future beststocks.com amg gle 63 s Nov 6, 2023 · According to the data, eight analysts have offered their 12-month price forecasts for ARQT stock. The median target price is $21.00, with a high estimate of $50.00 and a low estimate of $4.00. This indicates a potential increase of 762.42% from the last recorded price of $2.44. Furthermore, the current consensus among the eight polled ... 3 дня назад ... (Nasdaq: ARQT) is an early commercial-stage medical ... The definitive RECAF stock price forecast.